Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rabusertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 known ✓ | O14757 | 13/20 | 0.75 |
| ▸ | FECH | P22830 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304858 | 0.87 | CHEK1 (0.53) | CHEK1FECHKCNH2CHEK2AKT1 | |
| SCHEMBL304759 | 0.87 | CHEK1 (0.74) | CHEK1FECHKCNH2CHEK2AKT1 | |
| SCHEMBL304760 | 0.87 | CHEK1 (0.74) | CHEK1FECHKCNH2CHEK2AKT1 | |
| SCHEMBL305349 | 0.87 | CHEK1 (0.74) | CHEK1FECHKCNH2CHEK2AKT1 | |
| Rabusertib SCHEMBL304747 | 0.86 | CHEK1 (1.00) | CHEK1FECHKCNH2CHEK2 | |
| Rabusertib SCHEMBL304748 | 0.86 | CHEK1 (1.00) | CHEK1FECHKCNH2CHEK2 | |
| Rabusertib SCHEMBL30403507 | 0.86 | CHEK1 (1.00) | CHEK1FECHKCNH2CHEK2 | |
| SCHEMBL4506559 | 0.85 | CHEK1 (0.56) | CHEK1FECHKCNH2 | |
| SCHEMBL306791 | 0.83 | CHEK1 (0.67) | CHEK1FECHKCNH2CHEK2AKT1 | |
| SCHEMBL304377 | 0.83 | CHEK1 (0.67) | CHEK1FECHKCNH2CHEK2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | CHEK1, CHEK2, PCNA | CHEK1 1/4885FECH 2006/4885KCNH2 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.